GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Spectrum Pharmaceuticals, Inc. (SPPI) [hlAlert]

Rating:
Buy SPPI
up 82.68 %

Spectrum Pharmaceuticals, Inc. (SPPI) rated Buy

Posted on: Wednesday,  Jul 25, 2007  11:25 AM ET by Lazard Capital

Lazard Capital rated Buy Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) on 07/25/2007, when the stock price was $4.10. Since
then, Spectrum Pharmaceuticals, Inc. has gained 82.68% as of 12/04/2015's recent price of $7.49.
If you would have followed this Lazard Capital's recommendation on SPPI, you would have gained 82.68% of your investment in 3054 days.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company?s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/25/2007 11:25 AM Buy
None
4.10 6.00
as of 8/27/2015
1 Week up  0.13 %
1 Month up  2.18 %
3 Months up  9.82 %
1 YTD down  -15.36 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy